EntryPoint Capital LLC Acquires New Shares in Twist Bioscience Co. (NASDAQ:TWST)

EntryPoint Capital LLC bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,040 shares of the company’s stock, valued at approximately $420,000.

Several other institutional investors also recently bought and sold shares of TWST. Thrivent Financial for Lutherans increased its holdings in shares of Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after acquiring an additional 532,040 shares during the last quarter. State Street Corp grew its holdings in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Wellington Management Group LLP grew its holdings in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after purchasing an additional 521,272 shares during the last quarter. Jennison Associates LLC raised its position in shares of Twist Bioscience by 80.2% in the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after purchasing an additional 302,884 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Twist Bioscience by 63.5% in the fourth quarter. American Century Companies Inc. now owns 756,352 shares of the company’s stock worth $35,148,000 after buying an additional 293,751 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on TWST shares. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Wolfe Research started coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.40.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,259 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65. Following the completion of the transaction, the senior vice president now directly owns 132,014 shares in the company, valued at $6,514,890.90. This represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,726 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the sale, the chief executive officer now owns 660,966 shares in the company, valued at $27,549,062.88. This represents a 0.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,799 shares of company stock valued at $1,593,944 over the last quarter. 3.01% of the stock is owned by company insiders.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $44.25 on Wednesday. The firm has a market capitalization of $2.64 billion, a PE ratio of -13.09 and a beta of 2.15. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The business’s 50 day moving average is $45.45 and its 200-day moving average is $45.36.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the previous year, the company earned ($0.75) earnings per share. The business’s revenue was up 24.1% compared to the same quarter last year. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.